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Human platelet glycoprotein IIb (GPIIb) and IIIa (GPIIIa) form a Ca 2f-dependent heterodimer, the integrin GPIIb/IIIa, which functions as the 
fibrinogen receptor at the surface of activated platelets. GPIIB and GPIIIa are synthesized as single polypeptides from single messages and their 
amino acid sequences were derived from their cDNAs. The GPIIb precursor is proteolytically processed to yield the known disulphide-bonded 
two-chain (GPIIba and GPIIbB) covalent structure found in mature GPIIb. Our present protein chemical and mass spectrometric analyses indicate 
that the GPIIb precursor is proteolytically cleaved at two or three sites, to give rise to an homogeneous u-chain (GPIIb l-856) single disulphide- 
bonded to one of the two p-chains, which are present in a nearly 1: 1 ratio: GPIIb/?l (860-1008), with pyroglutamic acid as its blocked N-terminal 
residue; and GPIIb/32 (872-1008), with the already known N-terminal sequence. These results satisfy the previously observed electrophoretic size- 
heterogeneity of the /?-chain, confirmed the potential cleavage sites in the junction region, and indicate a probable dual proteolytic processing of 
GPIIb, which may be relevant o the rest of the two-chain a-subunits of the integrin family. 
Platelet glycoprotein IIb; a-Chain C-terminus; B-Chain N-terminus heterogeneity; Posttranslational proteolytic processing 
1. INTRODUCTION 
Glycoprotein IIb (GPIIb) of the human platelet 
plasma membrane is a 136 kDa two-chain bitopic pro- 
tein [l-3], which together with glycoprotein IIIa 
(GPIIIa), a 91 kDa bitopic membrane protein [I ,2], 
forms a Ca2+-dependent heterodimer [4], the integrin 
GPIIb/IIIa [5,6], which serves as the receptor for 
fibrinogen and other adhesive proteins upon platelet 
activation [7]. The GPIIb precursor gene spans about 
17 kb on the long arm of chromosome 17 [8], and con- 
tains 30 exons [9]. Biosynthetic studies in human 
megakaryocyte [lo] and HEL cell [ 1 l] confirmed the 
observation that GPIIb is synthesized as a single-chain 
precursor [12], whose amino acid sequence was cDNA- 
derived [9,13]. Like other integrin a-subunits, GPIIb is 
posttranslationally cleaved after being assembled with 
GPIIIa in the GPIIb/IIIa heterodimer [l 11. In mature 
GPIIb the heavy-chain (GPIIba, 114 kDa) is single 
disulphide-bonded to the light-chain (GPIIbP, 22 kDa) 
between the last cysteine of GPIIba and the first of 
GPIIb,& [14]. Although the disulphide bond and 
glycosylation patterns of GPIIb and the C-terminal of 
GPIIbfi have already been chemically determined 
[14-161, the present study on the structural conse- 
quences of the posttranslational cleavage of GPIIb was 
begun to clarify the electrophoretic size-heterogeneity 
of GPIIbfl [3] and some apparent discrepancies on the 
N-terminal sequence of GPIIb,&. While N-terminal se- 
quence analysis indicated that GPIIb,& begins at posi- 
tion 872 (LQDPV...) [14,17], Loftus et al. [18] 
suggested that the GPIIbP N-terminus is blocked. They 
also raised an antiserum against a synthetic peptide 
analogous to the predicted 859-871 peptide stretch of 
GPIIb, which recognized GPIIbfl by immunoelec- 
troblotting analysis. Here we have characterized the C- 
terminus of the a-chain and the heterogeneity of the N- 
terminus of the P-chain, which indicate a probable dual 
proteolytic processing of GPIIb. 
2. MATERIALS AND METHODS 
2.1. Materials 
Correspondence address: J. Gonzalez-Rodriguez, Instituto de 
Quimica Fisica, CSIC, Serrano 119, 28006 Madrid, Spain 
Abbreviations: GPIIb, GPIIIa, and GPIIb/IIIa, glycoproteins IIb, 
IIIa, and the heterodimer formed by them, respectively; CM-CPIIba 
and CM-GPIIbfl, the cy- and &chains of GPIIb, after full reduction 
and alkylation of GPIIb 
TPCK-trypsin and endoprotease Lys-C were from Sigma and 
Boehringer-Mannheim, respectively, and the porous glass beads 
(CPG-10, 200 mesh, 375 A pore diameter) from Corning. GPIIb and 
its fully reduced and alkylated chains, CM-GPIIbcr and CM-GPIIb,9, 
were isolated as previously described [3,19]. The C-terminal 19 kDa 
CNBr product of cleavage of CM-GPIIbcr was prepared as in [14] 
and isolated by reverse-phase HPLC on a C4 Vydac column (25 x 
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0.4 cm, pore size 30 pm, particle size 10 pm) equilibrated in a mixture 
of 0.1% trifluoroacetic acid in water (A) and 0.1% trifluoroacetic 
acid in acetonitrile (B) (90% A/10% B), and eluted at 1 ml/min first 
isocratically for 5 min, followed by a linear gradient up to 50% B in 
90 min. 
2.2. Methods 
Protein assay was done by amino acid analysis on a Biotronik 
analyzer after hydrolysis at 110°C in 6 N HCl for 24 h. N-terminal 
sequence analyses were carried out using either a Beckman 890C spin- 
ning cup or an Applied Biosystems 470 gas-phase sequencer [20]. 
Electroblotting of SDS/PAGE peptide bands into polyvinylidene 
difluoride membranes was performed following 1211. 
CM-GPIIbB (10 mg/ml) in 50 mM ammonium bicarbonate, 0.1% 
(V/V) N-ethylmorpholine, pH 8.0, was digested with trypsin at an en- 
zyme/substrate ratio 1: 100 (w/w) for 18 h at 37°C. The 19 kDa 
CNBr product of GPlIbcv (5 mg/ml) in 0.1 M Tris-HCl, pH 8.6, was 
digested with endoprotease Lys-C at an enzyme/peptide ratio 1:25 
(w/w) for 24 h at 37°C. Both tryptic and endoLys-C digestion pro- 
ducts were isolated by reverse-phase HPLC, as indicated above. 
Peptide C-terminal sequence determination was carried out accor- 
ding to (221 with minor modifications described in [16]. Mass spectra 
were recorded with a mass spectrometer HSQ 30 (Finnigan MAT, 
Bremen) equipped with an atom gun (Ion Tech. Ltd., Teddington, 
UK). Peptides were dissolved in acetonitrile/acetic acid/water 
(50: 10: 40 v/v) and mixed with glycerol 1231. 
3. RESULTS AND DISCUSSION 
3.1. The GPIIbp N-terminal heterogeneity 
To find out the structural bases of the size-hetero- 
geneity of the &chain of GPIIb, CM-GPIIb,f3 was sub- 
jected to SDS/12% polyacrylamide gel electrophoresis 
(Fig. 1) where it splits in two separate bands, about 
40% of fll, the larger, and 60% of p2, as determined 
by densitometry. These bands were subsequently elec- 
troblotted into polyvinylidene difluoride membranes 
and subjected to gas-phase N-terminal sequence 
analysis, where ,&2 yielded the already chemically deter- 
mined N-terminal sequence of GPIIbP (872 
LQDPV...), whereas the fll N-terminus was found 
blocked. To determine this blocked N-terminus, CM- 
GPIIbP was digested with trypsin and the tryptic pro- 
ducts, after separation by reverse-phase HPLC 
(Fig. 2), were identified by N-terminal sequence and 
amino acid analyses. All the obtained fractions had se- 
quenceable material, except for fraction 2, whose 
amino acid analysis clearly let us assign it to the peptide 
stretch 860 QIFLPEPEQPSR 871 in the predicted se- 
quence of GPIIb [13]. Mass spectrometric analysis of 
fraction 2 (Fig. 3), besides confirming this assignment, 
also showed that the blocked N-terminus of GPIIb,&l is 
a pyroglutamic acid residue (M + H+ calculated 1422.6, 
found 1422.9). These results explain the previously 
found heterogeneity of GPIIbP [3] and confirm the 
suggestion that the N-terminus of GPIIb@ is readily 
blocked [18]. However, our data differ quantitatively 
from those of Loftus et al. [18]. While they estimated 
that ,&2 represents as little as 3% of mature GPIIbfl, we 
have always found a ,&I/,&? ratio of nearly 1: I in our 
preparations from outdated platelet concentrates. Fur- 
ther experiments will have to be designed to ascertain 
38 
Fig. 1. Analysis of the size-heterogeneity of the fully reduced and 
alkylated p chain of GPIIb by SDS-12% polyacrylamide gel 
electrophoresis and Coomassie blue staining. The blocked N- 
terminus of the 81 chain and the chemically determined N-terminal 
sequence of the p2 chain are indicated on the right-hand side. 
whether ,&2 is formed at the same stage as Pl, or 
whether it is formed at later stages during thrombo- 
genesis, in the blood stream or during blood bank 
storage. 
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Fig. 2. Isolation by reverse-phase HPLC of the tryptic peptide 
carrying the blocked N-terminal sequence of GPIIbpl. The tryptic 
products of digestion of CM-GPIIba were isolated on a C4 Vydac 
column equilibrated in a mixture of 0.1% trifluoroacetic acid in 
water (v/v) (A) and 0.1% trifluoroacetic acid in acetonitrile (B) (9O@/‘o 
A/10% B) and eluted at 1 ml/min, first isocratically for 5 min, 
followed by a linear gradient up to 70% of B in 60 min. The 
chemically determined N-terminal sequence for each fraction is 
indicated, except that for fraction 2, which contains the peptide 
carrying the blocked N-terminus of the fll chain. 
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Fig. 3. Fast atom bombardment mass spectrometry of the tryptic peptide of CM-GPIIbfi from fraction 2 in Fig. 2, which confirms the chemically 
determined sequence of this peptide @l 860-871) and identifies the blocked N-terminus of GPIIl@l as a pyroglutamic acid residue. 
3.2. The localization of the Oterminus of GPIIba 
The above results raised the question of the actual 
location of the C-terminus of GPIIbcr within the GPIIb 
precursor sequence [9,13]. When CM-GPIIba, was 
digested with trypsin, and the tryptic products were 
isolated by reverse-phase HPLC (not shown) and sub- 
jected to amino acid and N-terminal sequence analyses, 
all the possible peptides around the cy-fl chain junction 
were obtained, except those upstream Lys-855, which 
F I Cycle 1 
s i? 
;7 
00 ~ 
5 10 15 20 m/n 
00 rk 
5 10 15 20 min 
Fig. 4. Chemical determination of the C-terminal sequence of the 
GPIIbcv chain. HPLC analysis of the thiohydantoin-amino acid 
derivatives from the first two cycles of C-terminal sequential 
degradation of the C-terminal 19 kDa CNBr-product of cleavage of 
CM-GPIIbcr, as described in section 2.2. Peaks are labelled using the 
one-letter symbols. 
let us deduce that the a chain C-terminus must be 
somewhere between Lys-855 and Arg-859, because 
residues upstream Arg-859 are already found in the 81 
chain. To locate the exact position of this C-terminus, 
the C-terminal 19 kDa CNBr-product of cleavage of 
CM-GPIIIJcY was prepared and isolated, and its C- 
terminal sequence chemically determined, as described 
in section 2.2. Two degradation cycles were successfully 
performed (Fig. 4), which allowed us to identify 
Lys-855 and Arg-856 as the last two residues of 
GPIIIxx, and to locate a third proteolytic cleavage site, 
besides the two already found (Fig. 5). 
Our results confirm the current hypothesis [24-271 
that the occurrence of integrin two-chain or single- 
chain ty subunits is related with the conservation of the 
sequence of the heavy-light chain junction region (be- 
tween residues 855 and 871 in the cDNA-derived GPIIb 
sequence), which contains the two consensus pairs of 
basic residues and the single basic residue preceded by 
a number of prolines and acid residues, which deter- 
mine the presence of the three proteolytic cleavage 
sites. The abnormal GPIIb found by Jung et al. [28] in 
the platelets of a thrombasthenic patient, which does 
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Fig. 5. Localization of the three proteolytic sites in the cDNA-derived 
amino acid sequence of the light-heavy chain junction region in the 
GPIIb precursor [13], together with the C-terminal sequence of 
GPIIbnr and the two N-terminal sequences of GPIIb@ (81 and ,&?). 
S-S represents the single interchain disulp~de bond [3], and Z in @l 
is the symbol for pyroglutamic acid. 
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not release the ,8 chain upon reduction, could be related 
to a lack or anomaly in exon 26, which codes for the 
cu-,L? chain junction region, although other genetic 
defects must be involved, because this abnormal GPIIb 
does not assemble in the GPIIb/IIIa heterodimer, 
which occurs at an earlier stage in the biosynthesis than 
the proteolytic processing [l I]. Finally, Bray et al. [29] 
have suggested that the size-heterogeneity of GPIIbP 
that we found [3] could be due to the splicing out of ex- 
on 28, corresponding to 34 amino acids of the ex- 
tracellular domain of GPIIb,&, among them ASN 60 (in 
,82): the single glycosylation point of GPIIbP [ 151. This 
does not seem to be the case, because both fil and ,82 
are glycosylated, and therefore, none of them can be 
the products of the transcript due to the splicing out of 
exon 28. 
Acknowledgements: Dr G.A. Rivas is gratefully acknowledged for 
his help in the preparation of GPIIb, CM-GPIIbcu and CM-GPIIb@. 
We also want to thank Dr D. Georgopoulous for helping with the 
amino acid analyses, Mrs G. Pinillos, Mrs H. Gross, Mrs B. Rinke, 
and Miss A. Vacas for technical assistance, Miss S. Salado for typing 
the manuscript, and the Blood Banks of Centro Ramdn y Cajal, La 
Paz and Dote de Octubre (Madrid) for providing us with outdated 
platelet concentrates. This work was supported by the DGICYT 
(PB 860629 and PM 88-0022) and an Acci6n Integrada Hispano- 
Alemana (1989-1990 43A). 
REFERENCES 
[l] Nurden, A.T., George, J.N. and Phillips, D.R. (1986) in: 
Biochemistry of Platelets (Phillips, D.R. and Shuman, M.A. 
eds) pp. 159-224, Academic Press, New York. 
[2] Usobiaga, P., Calvete, J.J., Saiz, J.L., Eirin, M.T. and 
Gonzalez-Rodriguez, J. (1987) Eur. Biophys. J. 14, 211-218. 
[3] Calvete, J.J. and Gonzalez-Rodriguez, J. (1986) Biochem. J. 
240, 155-161. 
[4] Kunicki, T.J., Pidard, D., Rosa, J.-P. and Nurden, A.T. (1981) 
Blood 58, 268-278. 
[5] Hynes, R.O. (1987) Cell 48, 549-554. 
[a] Phillips, D.R., Charo, I.F., Parise, L.V. and Fitzgerald, L.A. 
(1988) Blood 71, 831-843. 
[7] Marguerie, G.A., Ginsberg, M.H. and Plow, E.F. (1987) in: 
Platelets in Biology and Pathology, vol. 3 (MacIntyre, D.E. and 
Gordon, J.L. eds) pp. 95-125, Elsevier, Amsterdam. 
181 
]91 
1101 
illI 
WI 
[I31 
]141 
1151 
iI61 
1171 
t181 
v91 
WI 
t;:; 
1231 
1241 
WI 
WI 
1271 
WI 
1291 
Bray, P.F., Rosa, J.-P., Johnston, G.I., Shiu, D.T., Cook, 
R.G., Lau, C., Kan, Y.W., McEver, R.P. and Shuman, M.A. 
(1987) J. Clin. Invest. 80, 1812-1817. 
Heidenreich, R., Eisman, R., Surrey, S., Delgrosso, K., 
Bennett, J.S., Schwartz, E. and Poncz, M. (1990) Biochemistry 
29, 1232-1244. 
Duperray, A., Berthier, R., Chagnon, E., Ryckewaert, J.-J., 
Ginsberg, M.H., Plow, E.F. and Marguerie, G. (1987) J. Cell 
Biol. 104, 1665-1673. 
Rosa, J.-P. and McEver, R.P. (1989) J. Biol. Chem. 264, 
12596-12603. 
Bray, P.F., Rosa, J.-P., Lingappa, V.R., Kan, Y .W., McEver, 
R.P. and Shuman, M.A. (1986) Proc. Natl. Acad. Sci. USA 83, 
1480-1484. 
Poncz, M., Eisman, R., Heidenreich, R., Silver, S.M., Vilaire, 
G., Surrey, S., Schwartz, E. and Bennett, J.S. (1987) J. Biol. 
Chem. 262, 8476-8482. 
Calvete, J.J., Rivas, G., Alvarez, M.V., Hew, C.-L., 
Henschen, A. and Gonzalez-Rodriguez, J. (1989) Biochem. J. 
261, 551-560. 
Calvete, J.J., Henschen, A. and Gonzalez-Rodriguez, J. (1989) 
Biochem. J. 261, 561-568. 
Calvete, J.J., Schafer, W., Henschen, A. and Gonzalez- 
Rodriguez, J. (1990) FEBS Lett. 263, 43-46. 
Charo, I.F., Fitzgerald, L.A., Steiner, B., Rail, Jr., S.C., 
Bekeart, L.S. and Phillips, D.R. (1986) Proc. Natl. Acad. Sci. 
USA 83, 8351-8355. 
Loftus, J.C., Plow, E.F., Jennings, L.K. and Ginsberg, M.H. 
(1988) J. Biol. Chem. 263, 11025-11028. 
Eirin, M.T., Calvete, J.J. and Gonzalez-Rodriguez, J. (1986) 
Biochem. J. 240, 147-153. 
Edman, P. and Henschen, A. (1975) in: Protein Sequence 
Determination (Needleman, S.B. ed.) pp. 232-279, Springer, 
Berlin. 
Madsudaira, P. (1987) J. Biol. Chem. 262, 10035-10038. 
Hawke, D.H., Lahm, H.W., Shively, J.E. and Todd, R.W. 
(1987) Anal. Biochem. 166, 298-307. 
Naylor, S., Finders, A.F., Gibson, B.M. and Williams, D.H. 
(1986) J. Am. Chem. Sot. 108, 6359-6363. 
Argraves, W.S., Suzuki, S., Arai, H., Thompson, K., 
Pierschbacher, M.D. and Ruoslahti, E. (1987) J. Cell. Biol. 
105, 1183-1190. 
Suzuki, S., Argraves, W.S., Arai, H., Languino, L.R., 
Pierschbacher, M. and Rouslahti, E. (1987) J. Biol. Chem. 262, 
14080-14085. 
Corbi, A., Kishimoto, T.K., Miller, L.J. and Springer, T.A. 
(1988) J. Biol. Chem. 263, 12403-12411. 
Takada, Y. and Hemler, M.E. (1989) J. Cell Biol. 109, 
397-407. 
Jung, S.M., Yoshida, N., Aoki, N., Tanoue, K., Yamazaki, H. 
and Moroi, M. (1988) Blood 71, 915-922. 
Bray, P.F., Leung, C&I. and Shuman, M.A. (1990) J. Biol. 
Chem. 265, 9587-9590. 
40 
